Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1362.1 - Resubmission Cetuximab and RAS testing under MBS 73330

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat at

Please refer to the original application 1362 - Cetuximab and KRAS testing under MBS 73330
Application Number1362.1
Application NameResubmission Cetuximab and RAS testing under MBS 73330
Description of Medical ServiceCetuximab is used to treat patients with metastatic colorectal cancer (CRC). Cetuximab is a personalised medicine tailored to the genetic make-up of a patient. A patient’s cancer cells must therefore be tested to see if they contain the normal (“wild-type”) or a mutant form of a gene called RAS. Cetuximab is only used to treat metastatic CRC patients who have a normal RAS gene.
Description of Medical ConditionColorectal cancer, commonly known as colon or bowel cancer, is a cancer formed by uncontrolled cell growth in the colon or rectum (parts of the large intestine), or in the appendix. Symptoms of colorectal cancer typically include rectal bleeding and anemia, sometimes associated with weight loss and changes in bowel habits. Metastatic cancer is cancer that has spread from the place where it first started to other place(s) in the body. The symptoms and signs of metastatic colorectal cancer depend on the location of the tumour in the bowel and on where it has spread elsewhere in the body.
Consultation Protocol-
Final Protocol-
MSAC OutcomesPublic Summary Document 3 Oct 2014 (PDF 86 KB)
Public Summary Document 3 October 2014 (Word 106 KB)

Meetings for this Application

Meeting Type:Date:
MSAC 3 October 2014

Page currency, Latest update: 16 April, 2015